A study co-administrating the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) and enzalutamide has demonstrated enhanced inhibition of PC tumors by disrupting AR protein stability, thereby presenting a promising therapeutic intervention for mCRPC [56]. This evidence concerns the gene AR and pachyonychia congenita.